<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884104</url>
  </required_header>
  <id_info>
    <org_study_id>SMK-3</org_study_id>
    <nct_id>NCT00884104</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks</brief_title>
  <official_title>A Prospective, Open-label, Observational, Multi-center Study for the Identification of Predictive Factors for the Solifenacin Treatment in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks and Evaluation of Efficacy and Persistency of Add on Solifenacin in Men With Residual Overactive Bladder Symptoms After Previous Monotherapy With Tamsulosin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KYU-SUNG LEE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the rate of &quot;add-on&quot; solifenacin treatment and its
      persistency in men with over active bladder symptoms after tamsulosin monotherapy for 4
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center study to evaluate the efficacy, safety, and persistency of solifenacin
      treatment in male patients with persistent OAB symptoms of urinary frequency and urgency
      with/without urgency incontinence who are receiving tamsulosin monotherapy for LUTS at a
      stable dose for 4 weeks in real life practice. Also proportion of patients and predictive
      factors with persistent OAB symptoms after tamsulosin monotherapy will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with &quot;add-on&quot; solifenacin treatment</measure>
    <time_frame>Weeks of 12, 24 and 52 of combination therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in micturition efficacy parameters</measure>
    <time_frame>Weeks of 12, 24 and 52 of combination therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>1.tamsulosin + solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Oral</description>
    <arm_group_label>1.tamsulosin + solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IPSS ≥ 12

          -  Symptoms of OAB as verified by the V8 (≥8)

          -  Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:

               -  Mean urinary frequency ≥8 times/24 hours

               -  Mean number of micturition-related urgency episodes ≥3 episode/24 hours (with a
                  Urinary Sensation Scale rating of ≥3 marked for the corresponding micturition in
                  the bladder diary)

        Exclusion Criteria:

          -  Treatment within the 14 days preceding treatment with any alpha blocker drugs

          -  A known history of bladder outlet obstruction due to: bladder neck contracture,
             clinical suspicion of prostate carcinoma, mullerian duct cysts, urethral obstruction
             due to stricture/valves/sclerosis or urethral tumor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University School of Medicine, Kangnan-ku, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cheon-ju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Choongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kwang-ju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Solifenacin</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>OAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

